Back to search
FDAFDA · Food and drugs·Recall number D-0444-2024

Atovaquone Oral Suspension USP, 750 mg per 5 mL sachets, 20 Units x 5 mL cartons, Rx Only, Manufactured for: AvKARE, Pulaski, TN 38478, NDC 50268-086-12.

Published April 24, 2024 · Recall initiated: March 28, 2024

Summary

FDA records drug Class I recall D-0444-2024, published April 24, 2024 and initiated March 28, 2024. Recalling firm: AvKARE; Status: Terminated; Reported quantity: 153 cartons; Lot: Lot: AW0221A Exp. 08/30/2025. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Microbial contamination of a non-sterile product: potential Bacillus cereus contamination.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
AvKARE
Distributor
US Nationwide.
Lot
Lot: AW0221A Exp. 08/30/2025
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Atovaquone Oral Suspension USP, 750 mg per 5 mL sachets, 20 Units x 5 mL cartons, Rx Only, Manufactured for: AvKARE, Pulaski, TN 38478, NDC 50268-086-12. recalled?

Yes. FDA published recall D-0444-2024 on April 24, 2024. Reported hazard: Microbial contamination of a non-sterile product: potential Bacillus cereus contamination.

What should I do if I have this product?

Voluntary: Firm initiated · Letter